We examined the effects of PF1022A, newly developing in Japan, on adult Angiostrongylus cantonensis in the pulmonary arteries of rats. Following five and ten successive oral doses at 10 mg/kg per day, the firststage larvae in rat faeces disappeared completely at 2 weeks after treatment. The treatment completely killed the female worms, but not the male worms. However, numbers of male worms were also decreased after the administration of either five successive oral doses at 10 mg/kg per day for four courses or five successive intraperitoneal doses at 0.5 mg/kg per day. Next, we examined the effects of PF1022A on larval A. cantonensis migrating into the central nervous system (CNS) of rats. Following five successive oral doses at 5 or 10 mg/kg per day and five successive intraperitoneal doses at 0.5 mg/kg per day, lesser killing effects were ~ observed on male as well as female worms. On the basis of these results it is apparent that PF1022A will become a promising anthelmintic available as treatment for-tissuedwelling as well as intestinal nematodes,
Introduction
PF1022A produced in fermentation broth of strain PF1022 belonging to the order Agonomycetales (MyceIia Sterilia) has a unique structure of cyclic depsiJI~eptide.. It has been reported to be effective in vivo as well as in vitro against intestinal nematodes such as Asearis, galli in chickens, Toxocara canis and T. cati in dogs and Hae~ monchus contortus and Ostertagia ostertag~ in, cows and horses (Fukashe et al. 1990; Kurosawa et al; .. I992,: Sasa~i et al. 1992) . Its effects on intestinal nematodes are: characterized by prompt on,set of action. Using Angiostrongy= lus cantonensis in vitro, Terada (1992) PF1022A paralyzed worms synergistically by stimulating the gabergic mechanism and inhibiting the cholinergic mechanism; hence, the rapid action is explained by the neuropharmacological mechanism of action of the drug. In addition, the new anthelmintic seemed less toxic as judged from the higher doses required to achieve 50% lethality (LDs0 values) after intraperitoneal as well as oral administration (Sasaki et al. 1992) and from the surprising differences in the effective concentrations causing inhibition of the cholinergic mechanism in A. cantonensis and frog rectus (Terada 1992) . On the basis of these reports, PF1022A is thought to be a promising anthelmintic against intestinal nematodes.
If PF1022A is effective against tissue-dwelling nematodes in vivo, availability of this drug must increase. PF1022A was indeed strongly effective against larval A. costaricensis in mice, one of our experimental models for studying drug effects on tissue-dwelling nematodes . Almost complete killing effects were obtained by five successive doses of PF1022A given intraperitoneally at 0.625 mg/kg per day and orally at 10 mg/kg per day. It was also shown that the formulation of PF1022A had a marked influence on the absorption of the drug and that the formulation as oral cream was the best of the four formulations examined, To characterize further the basic properties of action of the anthelmintic on tissue-dwelling nematodes, in the present study we examined the effects of PF1022A against adult A. cantonensis in the pulmonary arteries and on larvae migrating into the central nervous system (CNS) of rats.
Materials and methods
Drug PFI:02ZA was kindly supplied by Meiji Seika Kaisha. This drug is essentially water-insoluble. For examination of the in vivo effects of PFt022A in this study, we used two formulations: the emulsi fled type designated as an oral cream and the solubilized type designated:as, an'oraI solution according to Terada et al. (1993) .
Infection
Experiment 3 Male Wistar rats aged 5 weeks were used as the final host. Infective third-stage larvae of Angiostrongylus cantonensis (Hawaiian strain) were obtained from experimentally infected snails, Biomphalaria glabrata (Puerto Rican strain), by artificial digestion using 0.04% pepsin in 0.7% HC1 for 30 min at 37 ~ C. Each rat was inoculated orally with 20 infective larvae of A. cantonensis.
Experimental design

Experiment 1
In this experiment we examined the effects of three regimens, i.e. five or ten successive and five intermittent oral doses of PF1022A in oral cream, on adult A. cantonensis in the pulmonary arteries of rats. Four infected groups of five rats each and one group of four rats without infection were used. Beginning at 8 weeks post-infection (p.i.), after confirmation of the onset of output of first-stage larvae in faeces from each rat, three groups were treated with five or ten successive daily doses of PF1022A at 10 mg/kg and five intermittent weekly doses at 10 mg/kg, respectively. Another infected group and a non-infected group were given only the vehicle for the oral cream and served as non-treated and non-infected controls, respectively.
The first-stage larvae detected in host faeces and host body weights were monitored until 18 weeks p.i. All surviving rats were killed at 18 weeks p.i. by an overdose of diethyl ether and then dissected. The number of worms recovered, the worm body length, the number of first-stage larvae detected per gram (dry weight) of faeces (LPG) and the distribution of first-stage larvae and eggs in lung tissues were examined as parameters in the worm. The relative weight (expressed in grams per 100 g body weight) of the heart-lungs and spleen, pathological changes in lung tissues as determined by visual or microscopical observation, the haemoglobin content (Hb) and the haematocrit (Hct) were examined as parameters in the host. The worm body length was estimated from photographs using a computerized image analyzer (Videoplan, Kontron Co., Munich, Germany; Ishii and Sano 1989) . LPG values were calculated by the method described by Kino (1984) , with some modifications. That is to say, the LPG value was calculated by multiplying the number of larvae per unit of fresh faeces by appropriate wet-dry ratio conversion factors, which ranged from 2.4 to 4.0, depending on the water content. Pathological changes were visually observed in each lobule; the degree of lesion formation was estimated as 1/5, 1/4, 1/3, 1/2 or 1/1, and total values were obtained by summing individual values for five lobules. Other parameters were examined according to the method described by Terada et al. (1993) . Significant differences between the values obtained were analyzed by Student's t-test.
Experiment 2
In this experiment we examined the effects of PF1022A in the oral cream given via a different route, i.e. orally or intraperitoneally, on adult A. cantonensis using five infected groups and one non-infected group of six rats each.
Beginning at 8 weeks p.i., two groups were treated orally with five successive doses of PF1022A at 10 mg/kg per day either once or four times every 10 days, respectively. Two groups were treated intraperitoneally with five successive doses of PF1022A at 0.5 mg/kg per day either once or twice at intervals of 4 weeks, respectively. In addition, one group with infection and one group without infection were given only the vehicle for the oral cream and served as non-treated and non-infected controls, respectively.
All surviving rats were killed at 18 weeks p.i. by an overdose of diethyl ether and then dissected. We determined all of the parameters examined in the worm and host in experiment 1 with the exception of haematological values.
In this experiment the effects of PF1022A on larval A. cantonensis migrating into the CNS of rats were examined using six groups of five rats each.
Beginning at 1 day p.i., two groups were treated orally with five successive daily doses of PF1022A in oral cream at 5 and 10 mg/kg, respectively. Two other groups were treated intraperitoneally with five successive daily 0.5-mg/kg doses of PF1022A in oral cream or in oral solution, respectively. One group with infection and one group without infection were given oral doses of only the vehicle for the oral cream and served as non-treated and noninfected controls, respectively.
All surviving rats were killed at 8 weeks p.i. by an overdose of diethyl ether and then dissected. Except for haematological values, all parameters analyzed in experiment 1 were examined.
Results
Effects of successive or intermittent oral doses of PF1022A on adult Angiostrongylus cantonensis in rats: experiment 1
One rat died at 46 days p.i., before treatment, in the group scheduled for intermittent dosing.
After five or ten successive oral doses of PF1022A at 10 mg/kg per day the first-stage larvae in rat faeces disappeared completely at 2 weeks after treatment and the larval disappearance persisted until dissection of the rats at 18 weeks p.i. (Fig. 1) . On the other hand, in the group treated intermittently with five weekly doses of 10 mg/kg a few larvae were observed during the experimental period.
At dissection at 18 weeks p.i., many eggs with various stages were found in the lung tissues of all rats in the non-treated control group (Table 1) . Eggs were not detected in rats in any of the treated groups except for three rats in the intermittently treated group, which had many developing eggs or a few eggs showing no development. The mean value for worm recovery was 18.2 worms in the non-treated control group. In the groups given five or ten successive doses a complete reduction in the number of female worms was observed, but the number of male worms did not decrease, resulting in a 65% reduction in the total worm count. In the intermittently treated group a somewhat lesser reduction was seen, even in the female worm count.
Little influence of PF1022A was observed on worm length. As compared with the values obtained in the noninfected control animals, there were a few non-significant changes in body weight and haematological values in the non-treated control group, although significant increases in the relative weight of heart-lungs and spleen were observed. Between the non-treated and treated groups, no significant change was seen in body weight or haematological values. As compared with the relative heart-lungs weight of 1.83 g/100 g body weight measured in the non-treated control group, this parameter decreased significantly in all treated groups. There was little influence on the relative spleen weight determined for the non-treated versus treated groups except in one group treated with ten successive oral doses.
With respect to microscopical pathological changes in the lung tissues, the degree of lesion formation was smaller in the treated groups, especially in the successively treated groups, than in the non-treated group. The microscopically determined changes agreed well with the visually observed (visible) pathological changes, and all values obtained in the treated groups were significantly lower than the 3.1 score recorded for the non-treated group.
Effects of oral and intraperitoneal doses of PF1022A on adult A. cantonensis in the pulmonary arteries of rats: experiment 2
One rat in the non-treated group and one rat in the group treated twice intraperitoneally died at 112 and 52 days p.i., respectively. The first-stage larvae in rat faeces disappeared completely at 2 weeks after treatment in all treated groups, and the larval disappearance persisted until dissection of the rats at 18 weeks p.i. following five successive oral doses of PF1022A at 10 mg/kg per day given once or four times at 10-day intervals and after five successive intraperitoneal treatments at 0.5 mg/kg per day given twice (Fig. 2) . On the other hand, in the group treated intraperitoneally with five successive doses at 0.5 mg/kg per day for one course only, a few larvae reappeared at 6 weeks after treatment. At dissection at 18 weeks p.i., many eggs with various stages were found in the lung tissues of all rats in the non-treated control group (Table 2) . Eggs were not detected in rats in any of the treated groups except for four rats in the intraperitoneally treated groups. Two rats from the group treated once had many eggs at various stages, and one rat from each group treated once or twice had only a few eggs showing no development.
The mean value for worm recovery was 16.0 worms in the non-treated control group. In the groups treated orally, almost a complete reduction in the number of female worms was observed, even in rats treated once with five successive doses, whereas the number of male worms decreased significantly only in the group treated with five successive doses for four courses, resulting in a 79% rate of reduction as compared with the non-treated control value. As a result, reductions in the total worm recovery of about 53% and 86% were observed in the groups treated with five successive oral doses for one and four courses, respectively. On the other hand, following five successive intraperitoneal doses at 0.5 mg/kg for one or two courses, a similar reduction of about 63% in female worms or 44% in male worms was seen. As a result, a reduction in the total worm recovery of about 53% was observed in the two groups treated once or twice with five successive intraperitoneal doses. As compared with the values obtained in the non-infected control animals, the body weight decreased significantly and the relative weight of heart-lungs and spleen increased significantly in the non-treated control. Significant changes were observed in the relative weight of heart-lungs and spleen and in body weight between the non-treated group and all treated groups except for one group treated four times with five successive oral doses.
With respect to microscopical pathological changes in the lung tissues, the degree of lesion formation in all treated groups was smaller than that in the non-treated group. The microscopically determined changes agreed well with the visually observed (visible) pathological changes, and all values obtained in the treated groups were significantly lower than that recorded for the nontreated group.
Effects of oral or intraperitoneal doses of PF1022A on larval A. cantonensis migrating into the CNS of rats: experiment 3
One rat in the non-treated group died at 55 days p.i., just before dissection. At dissection at 8 weeks p.i., as compared with the non-treated controls, all treated groups showed a significant reduction in the first-stage larval output in host faeces. Many eggs with various stages were found in the lung tissues of all rats in the non-treated control group and in all treated groups. Terada et al. (1993) only the total worm recovery was calculated because only a few worms were recovered from mice in many groups, especially those treated intraperitoneally. Thus, for comparison of those results with the present data (experiment 3), we again calculated the recovery of female and male worm separately and listed them above. Results are represented as mean values -+SE. Each rat was inoculated with 20 infective larvae. Treatments were done at 7-11 days p.i., and worms were recovered at dissection (37 or 38 days p.i.)
The mean value for worm recovery was 15.8 worms in the non-treated control group. In the groups treated orally, a significant reduction was observed in female and male worm recovery, respectively, resulting in a reduction of about 71% in the total worm count in both groups (Table 3 ). In the intraperitoneally treated groups, however, a smaller reduction in both female and male worms was observed, resulting a reduction of about 47% and 67%, respectively, in the total worm counts. The reduction in total worm count or female worm count was significant, and the effects were more extensive in the group treated with PF1022A in oral cream than in the group treated with the drug in oral solution. As compared with the length of female and male worms recovered from the non-treated controls, no significant difference was observed in the length of worms recovered from any of the treated groups, except for male worms recovered from the group treated intraperitoneally with PF1022A in oral cream.
As compared with the values obtained in the non-infected control animals, there were small changes (nonsignificant differences) in body weight and the relative weight of heart-lungs and spleen in the non-treated control group. Between the non-treated group and all treated groups, no significant change was seen in these parameters.
With respect to microscopical pathological changes in the lung tissues, the degree of lesion formation in all treated groups was only slightly lower than that in the non-treated group. The microscopically determined changes agreed well with the visually observed (visible) pathological changes, and all values obtained in the treated groups were lower and showed no significant difference as compared with the 2.2 score recorded for the non-treated group.
Discussion
In our examination of the effects of PF1022A on adult Angiostrongylus cantonensis in the pulmonary arteries of rats, we found that the drug (10 mg/kg) in oral cream had killing effects on adult A. cantonensis in the pulmonary arteries (experiment 1). Furthermore, it was suggested that the effects were stronger after successive dosing than following intermittent administration and that female worms were more susceptible to the drug than were male worms.
In experiment 2 we compared the effects of five successive doses of PF1022A (10 mg/kg) in oral cream when given once and four times every 10 days, and it became apparent that PF1022A was capable of killing male adult worms on repetition of the successive treatment. In this experiment the effects of five successive doses of PF1022A given intraperitoneally were also examined. We thought that if the drug were given intraperitoneally we could study more easily and more directly its mechanism of action because of the lack of processes of absorption in the intestinal tract. As compared with the effects observed in the groups treated orally, some killing effects on male worms and lesser effects on female worms were seen in the groups treated intraperitoneally. On the basis of the different effects on female and male worms observed between oral and intraperitoneal treatment, there seem to be some differences in the distribution and fate of the drug. It is likely that PF1022A given intraperitoneally acts like a sustained-release bolus.
From the results of experiments 1 and 2 it is apparent that PF1022A is effective against adult. A. cantonensis in the pulmonary arteries of rats.
Using the rat model of angiostrongyliasis cantonensis, Akyol et al. (1993) found that PF1022A did not seem to affect worms staying in the brain due to the scant distribution of the drug in the tissue. This finding is epochmaking because most gabergic anthelmintics are known to penetrate the blood-brain barrier of the host as reflected in their adverse side effects. In experiment 3 we therefore examined the effects of PF1022A on larval A. cantonensis migrating into the CNS of rats. As it had been reported that the infected larvae migrated into the CNS within 2 or 3 days p.i. (Wallace and Rosen 1969; Alicata and Jindrak 1970) , beginning at 1 day p.i. we gave rats five successive oral doses at 10 and 5 mg/kg per day, respectively. Killing effects were observed on male as well as female worms, but complete killing was not achieved, probably because larvae had migrated into the CNS during treatment. It was suggested that larval females were lower and larval males were higher in their susceptibility to PF1022A than were both sexes of adult A. cantonensis. A similar tendency was observed in our study exam-ining the anti-larval effects of PF1022A in murine angiostrongyliasis costaricensis (Table 4 ; Terada et al. 1993) .
From the data we obtained using A. cantonensis and A. costaricensis as model worms for studying the effects of drugs on diseases caused by tissue-dwelling nematodes in vivo, it is apparent that PF1022A has sufficient efficacy against tissue-dwelling adult and larval nematodes when it is given successively at least five times at relatively low doses of 10 (oral) and 0.5 mg/kg per day (intraperitoneal). It is also suggested that PF1022A may become more effective if a better formulation of the drug is devised for administration.
Apart from its efficacy, PF1022A has some epochmaking properties as compared with traditional antinematode anthelmintics. With regard to the mechanism of action of gabergic anthelmintics, it has been reported that all such drugs, including diethylcarbamazine, milbemycin derivatives, and avermectin derivatives, stimulate the gabergic mechanism when used at lower concentrations and also stimulate the cholinergic mechanism when applied at higher concentrations (Terada et al. 1994) . These effects are antagonistic in terms of regulating worm motility. On the other hand, piperazine and PF1022A act synergistically by stimulating the gabergic mechanism and inhibiting the cholinergic mechanism (Terada 1992; Terada et al. 1994) .
Recently a stronger suggestion that PF1022A does not pass through the blood-brain barrier has been reported. Terada et al. (1995) reported a conclusion similar to that described by Akyol et al. (1993) on the low efficacy of PF1022A against rat and murine angiostrongyliasis cantonensis. Cheng et al. (1995) reached a similar conclusion in studies on the effects of PF1022A on the CNS functions of rats and mice. They found that the sleeping time and food intake of animals were not affected by intravenous injection of PF1022A but were significantly influenced by intracerebroventricular injection of the drug. Thus, it is apparent that PF1022A has few adverse side effects that are related to passage through the bloodbrain barrier.
Furthermore, the median lethal doses (LDs0 values) of PF1022A for oral (p.o.) and intraperitoneal (i.p.) administration in mice, rats and dogs were 2000 mg/kg or higher (Terada 1993) . These values were greater than those found for ivermectin, i.e. 25 mg/kg p.o. and 30 mg/kg i.p. in mice (Campbell 1989) , and those reported for milbemycin D, i.e. 1547 and 1641 mg/kg p.o. in male and female mice, respectively and 668 and 772 mg/kg i.p. in male and female mice, respectively (Matsunuma et al. 1983) .
Finally, we conclude that PF1022A will become a promising anthelmintic available as treatment for both intestinal and tissue-dwelling nematodes.
